Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
Breast Cancer Research and Treatment, Volume 121, No. 1, Year 2010
Notification
URL copied to clipboard!
Description
The purpose of this trial was to determine cardiac toxicity and overall efficacy of the pegylated liposome doxorubicin (PLD)-docetaxel couplet alone if HER2-negative metastatic breast cancer (internal control) or with trastuzumab if HER2-positive disease. Upon central HER2 confirmation, 84 eligible patients received induction with PLD (30 mg/m2) and docetaxel (60 mg/m 2) every 3 weeks (maximum eight cycles), alone if HER2-negative (arm A; N = 38) or plus trastuzumab (4 mg/kg once, then 2 mg/kg weekly) if HER2-positive disease (arm B; N = 46) as first-line therapy. Maintenance therapy (without PLD) allowed. Primary objectives were to determine whether congestive heart failure (CHF) rate >3% and the efficacy/toxicity of each arm. CHF rate was <3% in each arm. Response rate, median progression-free-, and overall survival in arms A and B were 47.4 and 45.7%, 11 and 10.6 months, and 24.6 and 31.8 months, respectively. Trastuzumab arm was associated with higher rates of hand foot syndrome (grade 3: 22 vs. 38%; P = 0.16; overall 51 vs. 75%, P = 0.03) and treatment discontinuation due to toxicity/patient withdrawal (13 vs. 28%; P = 0.11). Febrile neutropenia occurred in ∼10% of patients. In conclusion, concurrent administration of trastuzumab with PLD-docetaxel was not associated with higher risk of cardiac toxicity compared with PLD-docetaxel alone, but led to excessive hand-foot syndrome. © 2010 Springer Science+Business Media, LLC.
Authors & Co-Authors
Wolff, Antonio C.
United States, Baltimore
The Sidney Kimmel Comprehensive Cancer Center
Wang, Molin
United States, Boston
Dana-farber Cancer Institute
Li, Hailun
United States, Boston
Dana-farber Cancer Institute
Pins, Michael R.
United States, Evanston
Northwestern University
United States, Park Ridge
Advocate Lutheran General Hospital
Pretorius, Florence J.
South Africa, Pretoria
University of Pretoria
Rowland, Kendrith M.
United States, Urbana
Carle Clinic
Sparano, Joseph A.
United States, New York
Albert Einstein Cancer Center of the Albert Einstein College of Medicine of Yeshiva University
Davidson, Nancy E.
United States, Baltimore
The Sidney Kimmel Comprehensive Cancer Center
United States, Pittsburgh
Upmc Hillman Cancer Center
Statistics
Citations: 26
Authors: 8
Affiliations: 8
Identifiers
Doi:
10.1007/s10549-010-0838-7
ISSN:
01676806
e-ISSN:
15737217
Research Areas
Cancer
Health System And Policy
Noncommunicable Diseases